173 related articles for article (PubMed ID: 22401729)
1. [Estimate of the 10-year risk of osteoporotic fractures in the Spanish population].
González López-Valcárcel B; Sosa Henríquez M
Med Clin (Barc); 2013 Feb; 140(3):104-9. PubMed ID: 22401729
[TBL] [Abstract][Full Text] [Related]
2. [FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population].
Azagra R; Roca G; Martín-Sánchez JC; Casado E; Encabo G; Zwart M; Aguyé A; Díez-Pérez A;
Med Clin (Barc); 2015 Jan; 144(1):1-8. PubMed ID: 24461732
[TBL] [Abstract][Full Text] [Related]
3. The burden of osteoporotic fractures: a method for setting intervention thresholds.
Kanis JA; Oden A; Johnell O; Jonsson B; de Laet C; Dawson A
Osteoporos Int; 2001; 12(5):417-27. PubMed ID: 11444092
[TBL] [Abstract][Full Text] [Related]
4. A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs.
Sander B; Elliot-Gibson V; Beaton DE; Bogoch ER; Maetzel A
J Bone Joint Surg Am; 2008 Jun; 90(6):1197-205. PubMed ID: 18519311
[TBL] [Abstract][Full Text] [Related]
5. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
Siris ES; Chen YT; Abbott TA; Barrett-Connor E; Miller PD; Wehren LE; Berger ML
Arch Intern Med; 2004 May; 164(10):1108-12. PubMed ID: 15159268
[TBL] [Abstract][Full Text] [Related]
7. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
8. [Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].
Naranjo A; Ojeda-Bruno S; Francisco-Hernández F; Erausquin C; Rúa-Figueroa I; Rodríguez-Lozano C
Med Clin (Barc); 2011 Mar; 136(7):290-2. PubMed ID: 21185575
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility and budget impact analysis of primary prevention with alendronate of osteoporotic hip fractures in Catalonia.
Pueyo MJ; Larrosa M; Surís X; Garcia-Ruiz AJ
Reumatol Clin; 2012; 8(3):128-34. PubMed ID: 22421456
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and economic burden of osteoporosis in Switzerland.
Svedbom A; Ivergård M; Hernlund E; Rizzoli R; Kanis JA
Arch Osteoporos; 2014; 9():187. PubMed ID: 24970672
[TBL] [Abstract][Full Text] [Related]
11. Establishing and evaluating FRAX
Chan DC; McCloskey EV; Chang CB; Lin KP; Lim LC; Tsai KS; Yang RS
J Formos Med Assoc; 2017 Mar; 116(3):161-168. PubMed ID: 27117886
[TBL] [Abstract][Full Text] [Related]
12. [Prevalence of risk factors for fragility fracture in men aged 40 to 90 years of a Spanish basic Rural Health Area].
Gómez Navarro R
Rev Esp Salud Publica; 2011 Oct; 85(5):491-8. PubMed ID: 22212836
[TBL] [Abstract][Full Text] [Related]
13. [Why do we close our eyes while the world is falling? A study on proximal femur osteoporotic fractures in a Portuguese population].
Cruz M
Acta Reumatol Port; 2009; 34(2B):370-7. PubMed ID: 19727048
[TBL] [Abstract][Full Text] [Related]
14. Preventing osteoporotic fractures in older people.
McCloskey E
Practitioner; 2011 Jan; 255(1736):19-22, 2-3. PubMed ID: 21370710
[TBL] [Abstract][Full Text] [Related]
15. Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database.
Maravic M; Le Bihan C; Landais P; Fardellone P
Osteoporos Int; 2005 Dec; 16(12):1475-80. PubMed ID: 16217587
[TBL] [Abstract][Full Text] [Related]
16. [General trend of hip fractures].
Chevalley T; Herrmann FR; Guilley E; Hoffmeyer P; Rizzoli R
Rev Med Suisse; 2011 Jun; 7(299):1294-8. PubMed ID: 21793418
[TBL] [Abstract][Full Text] [Related]
17. Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent Fracture: Analysis of a Large Population Sample.
Bawa HS; Weick J; Dirschl DR
J Bone Joint Surg Am; 2015 Oct; 97(19):1555-62. PubMed ID: 26446962
[TBL] [Abstract][Full Text] [Related]
18. Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort.
González-Macías J; Marin F; Vila J; Díez-Pérez A
Bone; 2012 Jan; 50(1):373-7. PubMed ID: 22129640
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
20. [Epidemiology of hip fracture in Asturias].
Altadill Arregui A; Gomez Alonso C; Virgós Soriano MJ; Diaz López B; Cannata Andía JB
Med Clin (Barc); 1995 Sep; 105(8):281-6. PubMed ID: 7475477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
